Escalation from Mesalamine to Advanced Therapy in Ulcerative Colitis

Introduction to Escalation Thresholds

• The British Society of Gastroenterology recommends lifelong maintenance therapy for all patients, especially those with left-sided or extensive disease, and those with distal disease who relapse more than once a year 1
• Patients who relapse more than once per year on mesalamine maintenance therapy meet the criteria for immunomodulator or biologic therapy 1, 2

Disease Severity and Treatment Selection

• Moderate-to-severe disease activity is an indication for direct biologic escalation 3, 4
• Extensive colitis is a factor that favors direct biologic therapy 1, 6
• Corticosteroid-dependent disease requires consideration of biologic therapy 2
• Young age is associated with higher relapse rates and may benefit from earlier aggressive therapy 7

Treatment Algorithms

• Azathioprine 1.5-2.5 mg/kg/day is appropriate for patients who relapse more than once per year as steroids are withdrawn 2
• The combination of infliximab and azathioprine achieves 39.7% corticosteroid-free remission at 16 weeks 5
• Vedolizumab monotherapy is an alternative first-line option if combination therapy is not feasible 5

Special Considerations

• Patients presenting with acute severe ulcerative colitis should be admitted to hospital immediately and started on IV methylprednisolone 40-60 mg/day 4, 7, 8
• Rescue therapy with IV infliximab or ciclosporin should be considered if there is no response to IV steroids by day 3-7 6, 8

Risk Stratification

• High-risk features favoring direct biologic therapy include extensive colitis, young age at diagnosis, severe endoscopic activity, elevated inflammatory markers, previous hospitalization for UC, and corticosteroid requirement for each relapse 1, 2, 7, 8
• Lower-risk features where azathioprine may be appropriate include distal colitis only, older age, mild endoscopic activity, and no corticosteroid dependency 1, 2, 7

Monitoring and Maintenance

• On azathioprine, FBC should be checked within 4 weeks and every 6-12 weeks thereafter 2
• On biologics, consider therapeutic drug monitoring to optimize dosing and prevent loss of response 3
• After any escalation, reassess disease extent within the first year to confirm diagnosis and predict disease course 9